These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 17471245)

  • 1. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell depletion therapy in rheumatic disease.
    Edwards JC; Cambridge G; Leandro MJ
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab.
    Kosmač M; Avčin T; Toplak N; Simonini G; Cimaz R; Curin Šerbec V
    Pediatr Res; 2011 Mar; 69(3):243-8. PubMed ID: 21131896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and use of therapeutic antibodies primarily of human origin.
    Stiehm ER; Keller MA; Vyas GN
    Biologicals; 2008 Nov; 36(6):363-74. PubMed ID: 18789721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New cytokine targets in inflammatory rheumatic diseases.
    Connell L; McInnes IB
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
    Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X
    Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis.
    Taylor RP; Lindorfer MA
    Nat Clin Pract Rheumatol; 2007 Feb; 3(2):86-95. PubMed ID: 17299446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.
    da Silva MA; Martins A; Teixeira AA; Reis RL; Neves NM
    Tissue Eng Part B Rev; 2010 Jun; 16(3):331-9. PubMed ID: 20025434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
    Eklund KK
    Immunol Rev; 2007 Jun; 217():38-52. PubMed ID: 17498050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-targeted immunotherapy.
    Janson RW; Arend WP
    Bull Rheum Dis; 1992; 41(3):6-8. PubMed ID: 1617334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals.
    Beresford MW; Baildam EM
    Arch Dis Child Educ Pract Ed; 2009 Oct; 94(5):151-6. PubMed ID: 19770495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody production: polyclonal-derived biotherapeutics.
    Newcombe C; Newcombe AR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):2-7. PubMed ID: 16893686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists.
    Kalden JR
    Curr Opin Rheumatol; 1994 May; 6(3):281-6. PubMed ID: 8060762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological therapies in rheumatic diseases.
    Conti F; Ceccarelli F; Massaro L; Cipriano E; Di Franco M; Alessandri C; Spinelli FR; Scrivo R
    Clin Ter; 2013; 164(5):e413-28. PubMed ID: 24217844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.